Genentech Says Lucentis DME Product Will Ship Shortly
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves lower, monthly 0.3 mg dose of injectable Lucentis for diabetic macular edema, the regimen Genentech had suggested was most appropriate. Questions remain about the commercial picture, considering competition from the similar but much cheaper Avastin.